We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
+12.24%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$649M
AUM Growth
-$93.5M
Cap. Flow
-$161M
Cap. Flow %
-24.86%
Top 10 Hldgs %
100%
Holding
11
New
–
Increased
4
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$12.1M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$12M
3
AMRN
Amarin Corp
AMRN
+$11.3M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$1.3M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$197M
2
MRSN
Mersana Therapeutics
MRSN
+$699K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
1
Ironwood Pharmaceuticals
IRWD
$696M
$188M 28.9%
16,390,000
– –
BIIB icon
2
Biogen
BIIB
$30B
$166M 25.64%
643,000
– –
INVA icon
3
Innoviva
INVA
$1.55B
$117M 17.99%
7,277,000
– –
GILD icon
4
Gilead Sciences
GILD
$162B
$87.1M 13.43%
1,075,400
+155,000
+17% +$12.1M
NBIX icon
5
Neurocrine Biosciences
NBIX
$16.8B
$61.9M 9.54%
470,000
+104,000
+28% +$12M
AMRN
6
Amarin Corp
AMRN
$299M
$21.6M 3.33%
1,242,531
+720,408
+138% +$11.3M
BCRX icon
7
BioCryst Pharmaceuticals
BCRX
$2.28B
$5.99M 0.92%
1,000,000
+225,000
+29% +$1.3M
VOR icon
8
Vor Biopharma
VOR
$1.15B
$1.39M 0.21%
30,900
– –
RGLS
9
DELISTED
Regulus Therapeutics
RGLS
$237K 0.04%
185,183
– –
ALKS icon
10
Alkermes
ALKS
$8.22B
– –
-7,042,200
Closed -$197M
MRSN
11
DELISTED
Mersana Therapeutics
MRSN
– –
-22,000
Closed -$699K

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Sarissa Capital Management held 11 positions worth $649M, down 13% from $742M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sarissa Capital Management withdrew a net $161M in Q4 2023, closing 2 positions. Its most notable exit was Alkermes, an estimated $197M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Sarissa Capital Management added an estimated $12.1M to Gilead Sciences.

  • Sarissa Capital Management added most to Gilead Sciences in Q4 2023, an estimated $12.1M increase.
  • Sarissa Capital Management fully exited Alkermes in Q4 2023, selling an estimated $197M.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $649M portfolio in Q4 2023.
  • Sarissa Capital Management opened 0 new positions and closed 2 in Q4 2023.
  • Sarissa Capital Management's portfolio value fell 13% quarter-over-quarter to $649M.

Based on Sarissa Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.